ANVS (Annovis Bio) Total Stockholders Equity : $24.05 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio Total Stockholders Equity?

Annovis Bio's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $24.05 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Annovis Bio's Book Value per Share for the quarter that ended in Mar. 2025 was $1.38. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Annovis Bio's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.00.

Annovis Bio Total Stockholders Equity Historical Data

The historical data trend for Annovis Bio's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio Total Stockholders Equity Chart

Annovis Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

7.54

44.50

28.32

-7.75

9.31

Annovis Bio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															-3.35	-1.75	7.06	9.31	24.05

Annovis Bio (NYSE:ANVS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Annovis Bio's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(24.054	-	0)	/	17.431
	=	1.38

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Annovis Bio's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	24.054
	=	0.00

Annovis Bio Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Annovis Bio's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Annovis Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

07X:Germany 07X:Germany

Address

101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355

Website

https://www.annovisbio.com

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Executives

Henry Iii Hagopian	officer: Chief Financial Officer	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White	director	227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck	director	4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini	director, officer: President and CEO	1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy	director	1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty	officer: Chief Financial Officer	360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M.	director	ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman	director	1 GREENWICH OFFICE PARK, GREENWICH CT 06831